Risking CRISPR correction before birth

CHOP-UPenn team leaves open to question risks of CRISPR gene editing in utero

A team from CHOP and UPenn has published its second study showing CRISPR-based gene editing can treat deadly diseases in the womb but has yet to address the safety repercussions for the mother and fetus.

In a study published this month in Science Translational Medicine, researchers

Read the full 454 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE